share_log

CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Mahatme Sandesh

CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Mahatme Sandesh

CRISPR Therapeutics | 4：持股变动声明-董事 Mahatme Sandesh
美股sec公告 ·  05/31 16:20
Moomoo AI 已提取核心信息
In a recent transaction, Sandesh Mahatme, associated with CRISPR Therapeutics AG (CRSP), executed a stock transaction on May 30, 2024. The specific details regarding the number of shares involved, the nature of the shares, the transaction price, and the post-transaction holdings were not disclosed in the announcement. Investors are advised to note the date of the transaction for any potential impact on the stock's performance.
In a recent transaction, Sandesh Mahatme, associated with CRISPR Therapeutics AG (CRSP), executed a stock transaction on May 30, 2024. The specific details regarding the number of shares involved, the nature of the shares, the transaction price, and the post-transaction holdings were not disclosed in the announcement. Investors are advised to note the date of the transaction for any potential impact on the stock's performance.
在最近的一笔交易中，与CRISPR Therapeutics AG（CRSP）相关的桑德什·马哈特梅于2024年5月30日执行了一笔股票交易。公告中未披露有关所涉股票数量、股票性质、交易价格和交易后持股量的具体细节。建议投资者注意交易日期，以了解对股票表现的任何潜在影响。
在最近的一笔交易中，与CRISPR Therapeutics AG（CRSP）相关的桑德什·马哈特梅于2024年5月30日执行了一笔股票交易。公告中未披露有关所涉股票数量、股票性质、交易价格和交易后持股量的具体细节。建议投资者注意交易日期，以了解对股票表现的任何潜在影响。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息